Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–66 of 66 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Guideline-based adjustment Clear all

Conditions: Heart Failure, Systolic, Depression, Cardiovascular Disease
Interventions: Collaborative Care for Heart Failure, Collaborative Care for Depression; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions: Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Human Milk, Neonate, Breast Milk
Interventions: Targeted Fortification, The Miris Human Milk Analyzer; Dietary Supplement · Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: Up to 6 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Diffuse Large B-cell-lymphoma
Interventions: Venetoclax, Rituximab, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: Molly Gallogly; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Diabetic Retinopathy
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 66
States / cities: Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Pharmacist collaboration in diabetes care, Usual care; Other
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 285 participants
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Staphylococcus Aureus Bacteremia
Interventions: Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging; Drug · Other · Radiation
Lead sponsor: University of Melbourne; Other
Eligibility: Not listed
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prevention and Control
Interventions: Webinar, Promotion, and Tool Access, LEAP, Audit and Feedback, Academic Detailing; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years to 80 Years
Enrollment: 17,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Ann Arbor, Michigan • Minneapolis, Minnesota • New York, New York + 5 more

Conditions: Asthma in Children
Interventions: Asthma-PASS, Basic Asthma Management (AM), Child/Caregiver Education session; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 4 Years to 12 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions: Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna; Drug · Radiation · Procedure
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 15 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more

Conditions: Psoriatic Arthritis
Interventions: Standard of care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 250 participants
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more

Conditions: Sleep, Pain
Interventions: ELDERFITNESS, Control; Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Optimized Treatment (OPT); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 14
States / cities: Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more

Conditions: Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF; Drug · Radiation · Other
Lead sponsor: Rafic Farah, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide; Procedure · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 39
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more

Search by objective public record fields.

Blended Collaborative Care for Heart Failure and Co-Morbid Depression

Allo HSCT Using RIC for Hematological Diseases

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Fenofibrate for Prevention of DR Worsening

Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes

Staphylococcus Aureus Network Adaptive Platform Trial

PrOVE QUERI Project #1

Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Treatment Goals in Psoriatic Arthritis

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

A Personalized Behavioral Intervention for Older Adults With Musculoskeletal Pain and Sleep Complaints

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)